Drug Approval | January 19, 2024
Lupin receives USFDA’s approval for Febuxostat Tablets
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
Subscribe To Our Newsletter & Stay Updated
